BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Avalglucosidase alfa-ngpt

Severe Hypersensitivity Reactions, Infusion-Associated Reactions, and Risk of Acute Cardiorespiratory Failure in Susceptable Patients

Hypersensitivity Reactions Including Anaphylaxis

  • Patients treated with NEXVIAZYME have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during NEXVIAZYME administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, NEXVIAZYME should be discontinued immediately and appropriate medical treatment should be initiated. In patients with severe hypersensitivity reaction, a desensitization procedure to NEXVIAZYME may be considered [see WARNINGS AND PRECAUTIONS (5.1)].

Infusion-Associated Reactions (IARs)

  • Patients treated with NEXVIAZYME have experienced severe IARs. If severe IARs occur, consider immediate discontinuation of NEXVIAZYME, initiation of appropriate medical treatment, and the benefits and risks of readministering NEXVIAZYME following severe IARs. Patients with an acute underlying illness at the time of NEXVIAZYME infusion may be at greater risk for IARs. Patients with advanced Pompe disease may have compromised cardiac and respiratory function, which may predispose them to a higher risk of severe complications from IARs [see WARNINGS AND PRECAUTIONS (5.2)].

Risk of Acute Cardiorespiratory Failure in Susceptible Patients

  • Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function for whom fluid restriction is indicated may be at risk of serious exacerbation of their cardiac or respiratory status during NEXVIAZYME infusion. More frequent monitoring of vitals should be performed during NEXVIAZYME infusion in such patients [see WARNINGS AND PRECAUTIONS (5.3)].

Patient Counseling Information

Package Inserts

avalglucosidase alfa 

Additional Information

Updated September 2021